Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02592317 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 72 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: details revised at 4 of 9 entries
  2. 7 versions Re-verified since Feb 12, 2026, no change to tracked fieldsv65-v71
  3. Trial status: Completed to Active, Not Recruiting
    • Study completion date: Oct 9, 2024 to Dec 31, 2027
    v64
  4. Trial status: Recruiting to Completed
    • Enrollment target: estimated 20 to confirmed 23
    • Study completion date changed from estimate of Dec 31, 2027 to Oct 9, 2024
    • Study sites revised (3)
    v63
  5. 7 versions Re-verified since Dec 5, 2024, no change to tracked fieldsv56-v62
Show 33 earlier versionsHide 33 earlier versions
  1. Primary completion date: Nov 2016 to Nov 7, 2016
    • Study completion date: Dec 2027 to Dec 31, 2027
    • Start date: Feb 2016 to Feb 12, 2016
    v55
  2. Primary completion date: Nov 7, 2016 to Nov 2016
    • Study completion date: Dec 31, 2024 to Dec 2027
    • Start date: Feb 12, 2016 to Feb 2016
    v54
  3. 2 versions Re-verified since Aug 13, 2024, no change to tracked fieldsv52-v53
  4. Primary completion date: Nov 2016 to Nov 7, 2016
    • Study completion date: Dec 2024 to Dec 31, 2024
    • Start date: Feb 2016 to Feb 12, 2016
    • Study sites revised (3)
    v51
  5. Re-verified, no change to tracked fieldsv50
  6. Primary completion date: Nov 7, 2016 to Nov 2016
    • Study completion date: Dec 31, 2024 to Dec 2024
    • Start date: Feb 12, 2016 to Feb 2016
    v49
  7. 3 versions Re-verified since Feb 27, 2024, no change to tracked fieldsv46-v48
  8. Trial status: Completed to Recruiting
    • Enrollment target: 23 to 20
    • Study completion date: Jan 18, 2023 to Dec 31, 2024
    v45
  9. Trial status: Active, Not Recruiting to Completed
    • Study completion date changed from estimate of Oct 15, 2023 to Jan 18, 2023
    v44
  10. 4 versions Re-verified since Oct 25, 2022, no change to tracked fieldsv40-v43
  11. Study completion date: Oct 15, 2022 to Oct 15, 2023v39
  12. 8 versions Re-verified since Jan 27, 2022, no change to tracked fieldsv31-v38
  13. Study completion date: Oct 15, 2021 to Oct 15, 2022v30
  14. 2 versions Re-verified since Sep 9, 2021, no change to tracked fieldsv28-v29
  15. Study completion date: Apr 15, 2021 to Oct 15, 2021v27
  16. Study completion date: Oct 15, 2020 to Apr 15, 2021v26
  17. Primary completion date: Nov 2016 to Nov 7, 2016
    • Study completion date: Oct 2020 to Oct 15, 2020
    • Start date: Feb 2016 to Feb 12, 2016
    v25
  18. Study completion date: Jun 2020 to Oct 2020v24
  19. Study completion date: Jan 2020 to Jun 2020v23
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the effects of repeat dosing of JNJ-56021927 on the pharmacokinetics for single-dose multiple cytochrome P450 (CYP450) enzymes (CYP3A4, CYP2C9, CYP2C19, CYP2C8) and transporter (P-gp and BRCP) substrates in participants with castration-resistant prostate cancer (CRPC).
Trial Details
NCT Number NCT02592317
Lead Sponsor Aragon Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Prostatic Neoplasms, Castration-Resistant
Related terms Prostatic Neoplasms, Castration-Resistant
Enrollment 23 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov